ArticleBMC surgery2026
A novel positive surgical margin-based scoring system to predict oncologic outcomes after radical prostatectomy.
Article in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Does active surveillance prior to radical prostatectomy increase the risk of adverse pathological findings or postoperative prostate cancer treatment?World journal of urology · 2026Article
- Impact of omitting contralateral systematic biopsy on clinically significant upgrading at radical prostatectomy: a retrospective paired-design study.International urology and nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe presence of positive surgical margins after radical prostatectomy is a well-established adverse prognostic factor. While some of these patients experience an aggressive clinical course, others do not. Making decisions about adjuvant or salvage treatment after positive surgical margins is particularly challenging. To better address this challenge, we present the results of a risk stratification model developed through detailed analysis of tumor characteristics at the surgical margin.
methodsWe retrospectively analyzed 63 patients with positive surgical margins after radical prostatectomy who had no lymph node involvement and had not received neoadjuvant or adjuvant therapy. The BEUN risk score integrates four pathologic features: number of positive foci, total margin extent, Gleason score at the margin, and concordance between margin and specimen grade. Based on the total score, patients were stratified into three risk categories: low risk (3–5 points), moderate risk (6–8 points), and high risk (9–12 points). Cox regression analysis identified predictors of biochemical recurrence-free survival (BRFS) and clinical progression-free survival (CPFS). Survival analyses across risk groups were performed using the Kaplan–Meier method.
resultsBiochemical recurrence occurred in 20 patients (32%) and clinical progression in 20 patients (32%). On multivariate analysis, the BEUN risk score independently predicted both BRFS (HR 1.23, 95% CI 1.08–1.40, p = 0.002) and CPFS (HR 1.28, 95% CI 1.06–1.54, p = 0.010). High-risk patients had a 4.7-fold higher hazard of biochemical recurrence (p = 0.001) and a 5.3-fold higher hazard of clinical progression (p = 0.011) compared with low-risk patients. Five-year BRFS rates were 58.8%, 24.1%, and 5.9% for low-, moderate-, and high-risk groups, respectively (p < 0.001).
conclusionThe BEUN risk score is an independent predictor of BRFS and CPFS. This tool may provide additional support for postoperative risk stratification in patients with positive surgical margins. CLINICAL
trial registrationNot applicable. This study is a retrospective observational cohort study and does not meet the criteria for clinical trial registration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.